Targeting B7x and B7-H3 as New Immunotherapies for Prostate Cancer
Technical Report,01 Sep 2014,31 Aug 2017
Albert Einstein College of Medicine, Inc Bronx United States
Pagination or Media Count:
We have made excellent progress during the three-year funding period, as evidenced by eight publications. We have shown the mechanisms by which B7x inhibits T cell function and promotes prostate cancer progress. We have solved structure of B7xIgV function domain and developed new mAbs to the IgV domain for a new cancer immunotherapy targeting B7x. Similarly, we developed new mAbs to the IgV domain of B7-H3 and are in the process of developing new cancer immunotherapy targetingB7-H3. We have discovered HHLA2 and TMIGD2 as the newest members of the B7-CD28 immune checkpoint family and further showed HHLA2 was highly expressed in human prostate cancer, which provided a potential new therapeutic target for human prostate cancer and other cancers as well.
- Medicine and Medical Research